Home›The Treatise›Chapters›Chapter 60
Tratado de Cirurgia da Coluna Vertebral
SECTION 7 • Other Spinal Diseases
Chapter60

METABOLIC BONE DISEASES AFFECTING THE SPINE

Vancouver: Gomes MM, Paula FJA📖 Pages: 783-792
Full reading of this chapter is available exclusively in the printed edition of the Treatise.
Sec. 7Other Spinal Diseases
Cap. 60Clinical Chapter
2authors
Português
Español
English
Referênciasscientific citations
📑

Chapter Summary

• Context: The vertebral column possesses heightened vulnerability to bone metabolic disturbances due to its high proportion of trabecular bone and active remodeling. These characteristics make vertebrae primary target sites for osteoporosis and diverse metabolic bone disorders. Vertebral fractures can be clinically silent and frequently go unrecognized, despite signaling a markedly elevated risk for subsequent fractures and substantial functional impairment. Diagnostic evaluation does not end with confirming osteoporosis: secondary causes significantly alter management and must be systematically investigated. This chapter covers primary osteoporosis, glucocorticoid-induced osteoporosis, primary hyperparathyroidism, rickets and osteomalacia, and Paget disease of bone. It further addresses the critical interpretation of dual-energy X-ray absorptiometry (DXA), morphometric assessment of vertebral compression fractures, and fracture risk calculation tools. For spine surgeons, understanding these disorders is essential because bone mineral quality, deformity, frailty, and calcium-phosphate metabolism directly impact fracture risk, implant purchase, and spinal reconstruction outcomes.
• Chapter Objective: Understand why the spine is uniquely sensitive to metabolic bone diseases; recognize primary osteoporosis and diagnose secondary etiologies; critically interpret DXA scans and identify morphometric vertebral fractures; understand the mechanisms and fracture risks of glucocorticoid therapy; and differentiate primary hyperparathyroidism, osteomalacia, rickets, and Paget disease based on clinical, biochemical, and imaging profiles.
• The spine as a metabolically active organThe preponderance of trabecular bone renders the spine highly responsive to shifts in bone turnover. This biological property explains why systemic bone loss associated with aging, estrogen deficiency, or pharmacological exposure manifests early and prominently in the vertebral bodies.
• Osteoporosis and vertebral fracturesOsteoporosis represents compromised bone strength predisposing to an increased risk of fracture. It is diagnosed by bone mineral density (T-score ≤ -2.5) or the occurrence of a low-trauma fragility fracture. Figure 60.1 demonstrates how technical acquisition errors, positioning artifacts, and incorrect vertebral labeling on DXA distort diagnostic interpretation. Vertebral fractures exhibit various morphological patterns (wedge, biconcave, crush), summarized in Figure 60.2, and many remain asymptomatic. Identifying an existing vertebral fracture alters risk stratification and mandates active secondary etiology workup.
• Glucocorticoid-induced osteoporosisGlucocorticoids rapidly suppress osteoblastogenesis and osteocyte viability while transiently stimulating osteoclastic resorption, in addition to impairing muscle function and intestinal calcium absorption. Fracture risk rises rapidly within months of exposure and is disproportionate to DXA BMD measurements. Clinical risk calculators must be adjusted for glucocorticoid dosage and duration.
• Primary hyperparathyroidismPrimary hyperparathyroidism is frequently uncovered during secondary osteoporosis workup. Unlike states of generalized high turnover, cortical bone resorption (e.g., distal radius) is often more pronounced than trabecular loss; thus, seemingly preserved spine BMD does not exclude severe disease. Table 60.1 details criteria for surgical parathyroidectomy.
• Rickets and osteomalaciaMineralization defects result from abnormalities in calcium, vitamin D, or phosphate homeostasis. The chapter distinguishes calcipenic and phosphopenic disorders. Figures 60.3 and 60.4 illustrate how X-linked hypophosphatemic rickets can lead to severe enthesopathy, spinal canal narrowing, and DXA findings that do not simply reflect low bone mass.
• Paget disease of bonePaget disease arises from disordered, focal osteoclastic hyperactivity followed by chaotic bone formation, commonly involving the spine. Most patients are asymptomatic, with diagnosis triggered by elevated alkaline phosphatase or characteristic radiographic features (picture frame vertebra, cotton wool appearance). Figure 60.5 exemplifies multilevel spinal involvement.
• Clinical Application: For the spine surgeon, poor bone quality should never be accepted as a simple, monolithic diagnosis. A fragility fracture, low T-score, or impending instrumentation failure requires determining whether primary postmenopausal/senile osteoporosis or a treatable secondary disorder is present. DXA scans require rigorous visual verification: degenerative osteophytes, aortic calcifications, or vertebral collapse falsely elevate lumbar BMD. Clinically silent vertebral compression fractures must be actively searched for on sagittal radiographs or vertebral fracture assessment (VFA). In patients taking glucocorticoids, moderate BMD T-scores can conceal high fracture risk, warranting aggressive bone-protective treatment. Hypercalcemia, hypophosphatemia, diffuse bone pain, and proximal muscle weakness point toward specific endocrinopathies or mineralization defects requiring metabolic co-management before elective spinal reconstructions.
🏷️

Keywords

Preferred DeCS/MeSH Descriptors:
OsteoporosisOsteoporotic FracturesBone DensityHyperparathyroidism, PrimaryOsteomalaciaRicketsRickets, HypophosphatemicOsteitis Deformans
⭐

Why this chapter matters

Bone quality directly governs fracture risk, spinal deformity progression, and the ability of spinal instrumentation to maintain stability without loosening or proximal junctional failure. However, radiologically similar osteopenia can stem from vastly different underlying biological mechanisms. This chapter equips the surgeon to critically evaluate DXA scans, identify occult vertebral fractures, and diagnose secondary metabolic disorders whose medical optimization drastically improves surgical outcomes.

“The spine is a sentinel organ for metabolic bone diseases. A vertebral fracture or low bone mineral density should not automatically be labeled as simple primary osteoporosis: glucocorticoid exposure, hyperparathyroidism, mineralization defects, and Paget disease alter diagnosis, fracture risk, and perioperative management. Accurate assessment requires integrating clinical history, biochemical markers, calcium-phosphate metabolism, and quality-controlled DXA analysis.”
✨

Chapter Highlights

🌐
Card 1 — Fractures Can Be Clinically Silent
Morphometric fractures

A substantial proportion of vertebral compression fractures produce no recognized acute clinical event. Height loss or incidental findings are often the first clues; identifying them fundamentally elevates future fracture risk.

🩺
Card 2 — Visually Inspect the DXA Scan
Scan quality control

The printed T-score report does not replace visual review of the acquisition images. Patient rotation, incorrect vertebral labeling, and degenerative osteophytes falsely elevate BMD readings, masking severe osteoporosis.

📐
Card 3 — Actively Investigate Secondary Causes
Secondary osteoporosis

Recognizing bone fragility mandates asking why. Glucocorticoids, hyperparathyroidism, malabsorption, and mineralization defects require specific medical therapies that alter spine surgery planning.

📑

How to Cite this Chapter (Vancouver Format)

Official bibliographic indexing and citation guidelines
📖 Pages: 783-792Vancouver Style
Authors (Vancouver):Gomes MM, Paula FJA

Gomes MM, Paula FJA. Doenças metabólicas que afetam a coluna. In: Pudles E, Defino H, Risso M, editors. Tratado de Cirurgia da Coluna Vertebral (Treatise of Spine Surgery). 1st ed. Rio de Janeiro: Dilivros Editora; 2026. p. 783-792.

ISBN: 978-85-8053-292-0 • 1.ª Edição • Dilivros Editora
📚

Bibliographic References

1. de Paula FJA, Black DM, Rosen CJ. Osteoporosis: basic and clinical aspects. In: Melmed S, Auchus RJ, Goldfine AB, Rosen CJ, Kopp PA, editors. Williams Textbook of Endocrinology. 15th ed. Philadelphia: Elsevier; 2024. p. 1233-75.
2. Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society. Menopause. 2021;28(9):973-97.
3. Cosman F, Lewiecki EM, Eastell R, Ebeling PR, Jan De Beur S, Langdahl B, et al. Goal-directed osteoporosis treatment: ASBMR/BHOF task force position statement 2024. J Bone Miner Res. 2024;39(10):1393-405.
4. International Society for Clinical Densitometry (ISCD). 2023 ISCD Adult Positions. 2023. Available from: https://iscd.org/wp-content/uploads/2024/03/2023-ISCD-Adult-Positions.pdf
5. Chotiyarnwong P, McCloskey EV. Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. Nat Rev Endocrinol. 2020;16(8):437-47.
6. Compston J. Glucocorticoid-induced osteoporosis: an update. Endocrine. 2018;60(1):7016.
7. Rahman A, Haider MF. A comprehensive review on glucocorticoids induced osteoporosis: a medication caused disease. Steroids. 2024;207(109440):109440.
8. Humphrey MB, Russell L, Danila MI, Fink HA, Guyatt G, Cannon M, et al. 2022 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol. 2023;75(12):2088-102.
9. Paccou J, Yavropoulou MP, Naciu AM, Chandran M, Messina OD, Rolvien T, et al. Prevention and treatment of glucocorticoid-induced osteoporosis in adults: recommendations from the European Calcified Tissue Society. Eur J Endocrinol. 2024;191(6):G1-17.
10. Bilezikian JF, Silverberg SJ, Bandeira F, Cetani F, Chandran M, Cusano NE, et al. Management of primary hyperparathyroidism. J Bone Miner Res. 2022;37(11):2391-403.
11. Baroncelli GI, Comberiati P, Aversa T, Baronio F, Cassio A, Chiarito M, et al. Diagnosis, treatment, and management of rickets: a position statement from the Bone and Mineral Metabolism Group of the Italian Society of Pediatric Endocrinology and Diabetology. Front Endocrinol (Lausanne). 2024;15:1383681.
12. da Silva MMR, Bilezikian JP, de Paula FJA. Phosphate metabolism: its impact on disorders of mineral metabolism. Endocrine. 2025;88(1):1-13.
13. Banaganapalli B, Fallatah I, Alsubhi F, Shetty PJ, Awan Z, Elango R, et al. Paget’s disease: a review of the epidemiology, etiology, genetics, and treatment. Front Genet. 2023;14:1131182.
14. Bouchette P, Boktor SW. Paget bone disease. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025.
15. Haridy Y, Witzmann F, Asbach P, Reisz RR. Permian metabolic bone disease revealed by microCT: Paget’s disease-like pathology in vertebrae of an early amniote. PLoS One. 2019;14(8):e0219662.
16. Singer FR, Bone HG 3rd, Hosking DJ, Lyles KW, Murad MH, Reid IR, et al. Paget’s disease of bone: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(12):4408-22.
17. Tuck SP, Walker J. Adult Paget’s disease of bone. Clin Med. 2020;20(6):568-71.
Episode 06 – Early-Onset Scoliosis
Scheduled Premiere
Exclusive Premiere • Wednesday, October 07 at 9:00 PM (BRT)
Wednesday, October 07 at 9:00 PM (BRT)
The live countdown will be activated on the eve of the premiere.

The full videocast will premiere automatically in this player on Wednesday, 10/07 at 6:00 PM (BRT).

Also premiering on Spotify
Treatise in Debate

Official videocast derived from the treatise chapters.

Episode 06 – Early-Onset Scoliosis

Lungs and the Growing Spine: thoracic development, C-EOS classification, and growth-friendly surgical techniques